Literature DB >> 7536892

Determination of the active site of CD59 with synthetic peptides.

Y Nakano1, T Tozaki, N Kikuta, T Tobe, E Oda, N Miura, T Sakamoto, M Tomita.   

Abstract

CD59 inhibits the formation of membrane attack complex (MAC) of human complement by binding to C8 and C9 in the nascent membrane attack complex and inhibiting C9 binding to C8 in C5b-8 and C9 polymerization. Considering five disulfide bridges of CD59, we divided the molecule into two portions and synthesized the two peptides. One represented an amino-terminal half, P1-41, consisting of residues 1-41, while another represented a carboxyl-terminal half, P42-77, consisting of residues 42-77. P1-41 inhibited the MAC formation much more strongly than P42-77, indicating that the amino-terminal half contained the active site. We further synthesized P4-18 that consisted of residues 4-18 and P19-41 that consisted of residues 19-41. The activity of P4-18 was less than that of P19-41. Surprisingly, P19-41 showed higher activity than P1-41 and was comparable to urine CD59. Residues 19-41 were further divided into two portions: P20-25 which consisted of residues 20-25 and P27-38 which consisted of residues 27-38. Although their activities were significantly less than the activity of P19-41, P27-38 showed higher activity than P20-25. Residues 27-38 were further divided into three portions: P27-32 which consisted of residues 27-32, P30-34 which consisted of residues 30-34 and P33-38 which consisted of residues 33-38. When these peptides were assayed for the activities, all of them showed significant activities, even though they needed 10-fold more concentrations than P19-41. These data suggest that the portion made up of residues 27-38 is the active site constituting the binding site to C8 and C9.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536892     DOI: 10.1016/0161-5890(94)00154-s

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  5 in total

1.  Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease.

Authors:  L B Yang; R Li; S Meri; J Rogers; Y Shen
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  Expression of rat CD59: functional analysis confirms lack of species selectivity and reveals that glycosylation is not required for function.

Authors:  N K Rushmere; S Tomlinson; B P Morgan
Journal:  Immunology       Date:  1997-04       Impact factor: 7.397

3.  Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59.

Authors:  D L Bodian; S J Davis; B P Morgan; N K Rushmere
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

4.  Production and functional characterization of a soluble recombinant form of mouse CD59.

Authors:  N K Rushmere; C W Van Den Berg; B P Morgan
Journal:  Immunology       Date:  2000-02       Impact factor: 7.397

5.  Overexpression of CD59 inhibits apoptosis of T-acute lymphoblastic leukemia via AKT/Notch1 signaling pathway.

Authors:  Yanfei Jia; Yan Qi; Yunshan Wang; Xiaoli Ma; Yihui Xu; Jun Wang; Xiaoqian Zhang; Meihua Gao; Beibei Cong; Shuyi Han
Journal:  Cancer Cell Int       Date:  2019-01-08       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.